Recent advances in the synthesis of endocannabinoid related ligands

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 21-33

  Razdan, R K ^a   Mahadevan, A ^a  

^a ORGANIX INC   (United States)

Author keywords

Cannabinoid receptors; Endocannabinoid system; Ligands; Structure activity relationships; Synthesis; Vanilloid receptors

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID DERIVATIVE; ESTER DERIVATIVE; FATTY ACID AMIDASE; LIGAND; VANILLOID RECEPTOR;

CARBON NUCLEAR MAGNETIC RESONANCE; CONFERENCE PAPER; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CARRIER PROTEINS; ENDOCANNABINOIDS; ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; GLYCERIDES; LIGANDS; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP;

ARA;

EID: 0037207073     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00142-1     Document Type: Conference Paper

References (60)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1893.
2. Beltramo M., Di Tomaso E., Piomelli D. Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene)tetrahydro-3-(1-napthalenyl)-2H-pyran-2-one. FEBS Lett. 403:1997;263-267.
3. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
4. Bezuglov V., Bobrov M., Gretskaya N., Gonchar A., Zinchenko G., Melck D., Bisogno T., Di Marzo V., Kuklev D., Rossi J.-C., Vidal J.-P., Durand T. Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg. Med. Chem. Lett. 11:2001;447-449.
5. Boger D.L., Miyauchi H., Hedrick M.P. α-keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and α-substitution. Bioorg. Med. Chem. Lett. 11:2001;1517-1520.
6. Childers S.R., Sexton T., Roy M.B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711-715.
7. Consroe P. Cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 5:1998;534-551.
8. Corey E.J., Iguchi S., Albright J.O., De B. Studies on the conformational mobility of arachidonic acid. Facile macrolactonization of 20-hydroxyarachidonic acid. Tetrahedron Lett. 24:1983;37-40.
9. Dasse O., Mahadevan A., Han L., Martin B.R., Di Marzo V., Razdan R.K. The synthesis of N-vanillyl-arachidonyl-amide (arvanil) and its analogs: an improved procedure for the synthesis of the key synthon methyl 14-hydroxy-(all-cis)-5,8,11-tetradecatrienoate. Tetrahedron. 56:2000;9195-9202.
10. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483:2000;52-56.
11. De Petrocellis L., Melck D., Ueda N., Maurelli S., Kurahashi Y., Yamamoto S., Marino G., Di Marzo V. Novel inhibitors of brain neuronal and basophilic anandamide amidohydrolase. Biochem. Biophys. Res. Commun. 231:1997;82-88.
12. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharm. 46:1993;791-796.
13. Deutsch D.G., Lin S., Hill W.A.G., Morse K.L., Salehani D., Arreaza G., Omeir R.L., Makriyannis A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Pharmacol. 53:1997;1-16.
14. Deutsch D.G., Makriyannis A. Inhibitors of anandamide breakdown. NIDA Res. Monogr. 173:1997;65-84.
15. Deutsch D.G., Omeir R., Arreaza G., Salehani D., Prestwich G.D., Huang Z., Howlett A. Methyl arachidonylfluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 53:1997;255-260.
16. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and Structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
17. Di Marzo V., Bisogno T., De Petrocellis L., Brandi I., Jefferson R.G., Winckler R.L., Davis J.B., Dasse O., Mahadevan A., Razdan R.K., Martin B.R. Highly Selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor 'hybrid' ligands. Biochem. Biophys. Res. Commun. 281:2001;444-451.
18. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Martin B.R. Cannabimimetic fatty acid derivatives: the anandamide family and other 'endocannabinoids'. Curr. Med. Chem. 6:1999;721-744.
19. Di Marzo V., Bisogno T., Melck D., Ross R., Brockie H., Stevenson L., Pertwee R., De Petrocellis L. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436:1998;449-454.
20. Di Marzo V., Griffin G., De Petrocellis L., Brandi I., Bisogno T., Williams W., Grier M.C., Kulasegram S., Mahadevan A., Razdan R.K., Martin B.R. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 300:2002;984-991.
21. Edgemond W.S., Greenberg M.J., McGinley P.J., Muthian S., Campbell W.B., Hillard C.J. Synthesis and characterization of diazomethylarachidonyl ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase. J. Pharmacol. Exp. Ther. 286:1998;184-190.
22. Giuffrida A., Piomelli D. The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chem. Phys. Lipids. 108:2000;151-158.
23. Griffin, G., Beletskaya, I., De Petrocellis, L., Mahadevan, A., Di Marzo, V., Razdan, R.K., Martin B.R. 2001. Activity of a Novel Anandamide Analog Suggests A Non-CB1, Non-VR1 Site of Action. International Cannabinoid Research Society (ICRS), Abstract #, p. 52.
24. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)-delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA. 95:1998;8268-8273.
25. Han L., Razdan R.K. Total Synthesis of 2-Arachidonylglycerol (2-Ara-Gl). Tetrahedron Lett. 40:1999;1631-1634.
26. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-arachidonylglyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;3662-3665.
27. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
28. Jarrahian A., Manna S., Edgemond W.S., Campbell W.B., Hillard C.J. Structure-activity relationships among N-arachidonyletanolamide (anandamide) head group analogues for the anandamide transporter. J. Neurochem. 74:2000;2597-2606.
29. Khanolkar A.D., Abadji V., Lin S., Hill W.A.G., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39:1996;4515-4519.
30. Khanolkar A.D., Makriyannis A. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sci. 65:1999;607-616.
31. Klein T.W., Newton C., Friedman H. Cannabinoid receptors and immunity. Immunol. Today. 19:1998;373-381.
32. Koutek B., Prestwich G.D., Howlett A.C., Chin S.A., Salehani D., Akhavan N., Deutsch D.G. Inhibitors of arachidonylethanolamide hydrolysis. J. Biol. Chem. 269:1994;22937-22940.
33. Lin S., Khanolkar A.D., Fan P., Goutopoulos A., Qin C., Papahadjis D., Makriyannis A. Novel analogues of arachidonylethanolamine (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem. 41:1998;5353-5361.
34. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc.Natl. Acad. Sci. USA. 97:2000;9561-9566.
35. Manna S., Falck J.R., Chacos N., Capdevila J. Synthesis of arachidonic acid metabolites produced by purified kidney cortex microsomal cytochrome P-450. Tetrahedron Lett. 24:1983;33-36.
36. Martin B.R., Beletskaya I., Patrick G., Jefferson R., Winckler R., Deutsch D.G., Di Marzo V., Dasse O., Mahadevan A., Razdan R.K. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294:2000;1209-1218.
37. Martin B.R., Mechoulam R., Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:1999;573-595.
38. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
39. Mechoulam R., Fride E., Ben-Shabat S., Meiri U., Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonyl glycerol, a hypotensive endocannabinoid. Eur. J. Pharmacol. 362:1998;R1-3.
40. Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., Di Marzo V. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun. 262:1999;275-284.
41. Ng E.W., Aung M.M., Abood M.E., Martin B.R., Razdan R.K. Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas. J. Med. Chem. 42:1999;1975-1981.
42. Parker L.A., Mechoulam R., Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport. 13:2002;567-570.
43. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
44. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:1999;635-664.
45. Pinto J.C., Potie F., Rice K.C., Boring D., Johnson M.R., Evans D.M., Wilken G., Cantrell C.H., Howlett A.C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:1994;516-522.
46. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.-Q., Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA. 96:1999;5802-5807.
47. Rodriguez M.L., Viso A., Gutierrez S.O., Becker I.L., Gonzales S., Ruiz J.F., Ramos J.A. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem. 44:2001;4505-4508.
48. Ryan W.J., Banner W.K., Wiley J.L., Martin B.R., Razdan R.K. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J. Med. Chem. 40:1997;3617-3625.
49. Seltzman H.H., Fleming D.N., Hawkins G.D., Carroll F.I. Facile synthesis and stabilization of 2-arachidonylglycerol via its 1,3-phenylboronate ester. Tetrahedron Lett. 41:2000;3589-3592.
50. Seltzman H.H., Fleming D.N., Thomas B.F., Gilliam A.F., McCalliom D.S., Pertwee R.G., Compton D.R., Martin B.R. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. J. Med. Chem. 40:1997;3626-3634.
51. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Stuctural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:1997;659-667.
52. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
53. Sugiura T., Kodaka T., Nakane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonylglycerol receptor. J. Biol. Chem. 274:1999;2794-2801.
54. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
55. Suhara Y., Nakane S., Arai S., Takayama H., Waku K., Ishima Y., Sugiura T. Synthesis and biological activities of novel structural analogues of 2-arachidonylglycerol, an endogenous cannabinoid receptor ligand. Bioorg. Med. Chem. Lett. 11:2001;1985-1988.
56. Suhara Y., Takayama H., Nakane S., Miyashita T., Waku K., Sugiura T. Synthesis and biological activities of 2-arachidonylglycerol, an endogenous cannabinoid receptor ligand, and its metabolically stable ether-linked analogues. Chem. Pharm. Bull. (Tokyo). 48:2000;903-907.
57. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB. 12:1998;1035-1044.
58. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
59. Wagner J.A., Varga K., Jarai Z., Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33:1999;429-434.
60. Wrigglesworth R., Walpole C.S.J., Bevan S., Campbell E.A., Dray A., Hughes G.A., James I., Masdin K.J., Winter J. Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. potent, orally active analgesics. J. Med. Chem. 39:1996;4942-4951.